Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: Case series and review

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 6, 2008, Pages 683-691

  Mariani, John J ^a,b   Levin, Frances R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Alcohol dependence; Anticonvulsants; Anxiety disorders

Indexed keywords

ETIRACETAM;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CASE REPORT; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; SEDATION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANXIETY DISORDERS; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIRACETAM;

EID: 56549109183     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802308213     Document Type: Article

References (36)

1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19):2511-2518.
2. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66(1):17-31.
3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6):617-627.
4. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61(8):807-816.
5. Burns L, Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well Being. Drug Alcohol Depend 2002; 68(3):299-307.
6. Schuckit MA, Tipp JE, Bucholz KK, Nurnberger JI Jr, Hesselbrock VM, Crowe RR, Kramer J. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction (Abingdon, England) 1997; 92(10):1289-304.
7. Schneider U, Altmann A, Baumann M, Bernzen J, Bertz B, Bimber U, Broese T, Broocks A, Burtscheidt W, Cimander KF, Degkwitz P, Driessen M, Ehrenreich H, Fischbach E, Folkerts H, Frank H, Gurth D, Havemann-Reinecke U, Heber W, Heuer J, Hingsammer A, Jacobs S, Krampe H, Lange W, Lay T, Leimbach M, Lemke MR, Leweke M, Mangholz A, Massing W, Meyenberg R, Porzig J, Quattert T, Redner C, Ritzel G, Rollnik JD, Sauvageoll R, Schlafke D, Schmid G, Schroder H, Schwichtenberg U, Schwoon D, Seifert J, Sickelmann I, Sieveking CF, Spiess C, Stiegemann HH, Stracke R, Straetgen HD, Subkowski P, Thomasius R, Tretzel H, Verner LJ, Vitens J, Wagner T, Weirich S, Weiss I, Wendorff T, Wetterling T, Wiese B, Wittfoot J. Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: the first Multicentre Study in Germany. Alcohol Alcohol 2001; 36(3):219-223.
8. Bakken K, Landheim AS, Vaglum P. Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences. A study of a consecutive sample of alcohol-dependent and poly-substance-dependent patients treated in two counties in Norway. Drug Alcohol Depend 2005; 80(3):321-328.
9. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54(4):313-321.
10. Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 2000; 20(2):149-171.
11. Schuckit MA, Hesselbrock V. Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiatry 1994; 151(12):1723-1734.
12. Allan CA. Alcohol problems and anxiety disorders-a critical review. Alcohol Alcohol 1995; 30(2):145-151.
13. Kushner MG, Abrams K, Thuras P, Hanson KL, Brekke M, Sletten S. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcohol Clin Exp Res 2005; 29(8): 1432-1443.
14. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22 Suppl 1:49-59.
15. Tollefson GD, Lancaster SP, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull 1991; 27(2):163-170.
16. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16(6):1007-1013.
17. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994; 51(9):720-731.
18. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, Brady KT, Davidson JR. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14(4):255-262.
19. Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. Journal of anxiety disorders 2008; 22(2):310-318.
20. Mariani JJ, Levin FR. Pharmacotherapy for alcohol-related disorders: what clinicians should know. Harv Rev Psychiatry 2004; 12(6):351-366.
21. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370):1677-1685.
22. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama 2007; 298(14):1641-1651.
23. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47(1-2):77-90.
24. Bauer J, Ben-Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenite DG. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta neurologica Scandinavica 2006; 114(3):169-176.
25. Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000; 42(2-3):89-95.
26. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clinical pharmacokinetics 2004; 43(11):707-724.
27. Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, Steinhoff BJ, Schulze-Bonhage A. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10(3):486-494.
28. Gower AJ, Falter U, Lamberty Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol 2003; 481(1):67-74.
29. Lamberty Y, Falter U, Gower AJ, Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. Eur J Pharmacol 2003; 469(1-3):97-102.
30. Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65(9):1219-1222.
31. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006; 67(10):1573-1576.
32. Lamberty Y, Gower AJ, Klitgaard H. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002; 439(1-3):101-106.
33. Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006; 26(3):347-349.
34. Carroll KM O.M.S, Nuro K. Compliance Enhancement: A Manual for the Psychopharmacology of Drug Abuse and Dependence. In Yale University Psychotherapy Development Center Training Series No. 4: West Haven, CT, 1999.
35. Hamilton M. The assessment of anxiety states by rating. Br J Psychiatry 1959; 32:50-55.
36. Sullivan J, Sykora K, Schneiderman J, Naranjo C, Sellers E. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84(11):1353-1357.